{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:21:13Z","timestamp":1785763273232,"version":"3.56.0"},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013263","name":"Nasjonalforeningen for Folkehelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013263","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2026,4]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Anti\u2010amyloid therapies, such as lecanemab or donanemab, represent the first disease\u2010modifying treatments approved for early Alzheimer's disease (AD) in individuals with confirmed amyloid pathology. Their implementation in routine care raises important challenges, particularly in older adults with heterogeneous functional reserve and multimorbidity. We address the role of frailty in refining clinical decision\u2010making for anti\u2010amyloid therapies.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This short communication presents a conceptual discussion informed by geriatric oncology, where frailty assessment and comprehensive geriatric assessment (CGA) are routinely used to individualize treatment in heterogeneous older populations. We describe how similar principles may be applied to anti\u2010amyloid monoclonal antibodies once regulatory eligibility has been established, and outline a frailty\u2010informed conceptual framework to support clinical decision\u2010making in routine care.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This conceptual analysis proposes a stepwise, frailty\u2010informed clinical framework that integrates regulatory eligibility assessment with brief frailty screening and targeted comprehensive geriatric assessment. The framework defines differentiated clinical pathways for robust, pre\u2010frail, and frail individuals, linking frailty status to specific decisions regarding treatment initiation, need for prehabilitation, intensity of monitoring, and consideration of treatment deferral. By embedding frailty assessment within routine clinical workflows, the framework operationalizes evaluation of physiological reserve, anticipates treatment burden and monitoring feasibility, and provides a structured approach to individualized risk\u2013benefit appraisal for anti\u2010amyloid therapies.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Frailty\u2010informed frameworks may offer a pragmatic and ethically grounded approach to support real\u2010world implementation of anti\u2010amyloid therapies, guiding treatment selection as well as longitudinal decisions on monitoring, continuation, and reassessment over time.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ene.70567","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T05:55:37Z","timestamp":1775454937000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Older Adults, Anti\u2010Amyloid Therapy, and Frailty: What Oncology Can Teach Us"],"prefix":"10.1111","volume":"33","author":[{"given":"Miguel Germ\u00e1n","family":"Borda","sequence":"first","affiliation":[{"name":"Department of Neurology Cl\u00ednica Universidad de Navarra Pamplona Spain"},{"name":"Centre for Age\u2010Related Medicine (SESAM), Stavanger University Hospital Stavanger Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6220-7310","authenticated-orcid":false,"given":"Kevin","family":"O'Hara\u2010Veintimilla","sequence":"additional","affiliation":[{"name":"Psychogeriatric Unit Cl\u00ednica Josefina Arregui Alsasua Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[{"name":"Centre for Age\u2010Related Medicine (SESAM), Stavanger University Hospital Stavanger Norway"},{"name":"Centre for Healthy Brain Aging, Department of Psychological Medicine, IoPPN King's College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanhl.2024.100666"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.70190"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100094"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf017"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)01789\u2010X"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8347"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102025\u2010336597"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603\u2010012\u20100084\u20102"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afw242"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S365494"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40520\u2010018\u20101004\u2010z"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_2_9_15_1","unstructured":"\u201cAccess\u2010Ad\u2014Ensuring Timely Diagnosis and Equitable Treatment for Alzheimer's Disease Across Europe \u201d accessed January 25 2026 (2026) https:\/\/www.access\u2010ad.org\/."}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70567","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.70567","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:54:13Z","timestamp":1778054053000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.70567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/ene.70567"],"URL":"https:\/\/doi.org\/10.1111\/ene.70567","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70567"}}